-
1.发明申请MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE 审中-公开包含低溶解性药物和携带者的多重试验结果发生在快速释放药物公开(公告)号：US20110027372A1
公开(公告)日：2011-02-03
申请号：US12902033
申请日：2010-10-11
申请人： Leah Elizabeth Appel , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , Joshua Richard Shockey
发明人： Leah Elizabeth Appel , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , Joshua Richard Shockey
IPC分类号： A61K9/14
CPC分类号： A61K9/1617 , A61K9/1623 , A61K9/1694
摘要： Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.
摘要翻译： 公开了导致药物快速释放的低溶解度药物和载体的多微粒。
-
2.发明申请Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release 审中-公开包含低溶解度药物和载体的多种颗粒导致快速的药物释放公开(公告)号：US20090142401A1
公开(公告)日：2009-06-04
申请号：US11920468
申请日：2006-05-26
申请人： Leah Elizabeth Appel , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , Joshua Richard Shockey
发明人： Leah Elizabeth Appel , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , Joshua Richard Shockey
CPC分类号： A61K9/1617 , A61K9/1623 , A61K9/1694
摘要： Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.
摘要翻译： 公开了导致药物快速释放的低溶解度药物和载体的多微粒。
-
公开(公告)号：US06984403B2
公开(公告)日：2006-01-10
申请号：US10763340
申请日：2004-01-23
申请人： Timothy A. Hagen , Julian B. Lo , Avinash G. Thombre , Scott M. Herbig , Leah Elizabeth Appel , Marshall David Crew , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , James Blair West
发明人： Timothy A. Hagen , Julian B. Lo , Avinash G. Thombre , Scott M. Herbig , Leah Elizabeth Appel , Marshall David Crew , Dwayne Thomas Friesen , David Keith Lyon , Scott Baldwin McCray , James Blair West
IPC分类号： A61K9/14
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
摘要： The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
摘要翻译： 本发明涉及包含有效量的碱化剂和阿奇霉素多颗粒的口服剂型，其中所述多颗粒包含阿奇霉素，其包含甘油单硬脂酸甘油酯，二苯乙酸甘油酯，枸橼酸甘油酯或其混合物和泊洛沙姆的甘油酯。 通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。
-
公开(公告)号：US20100003331A1
公开(公告)日：2010-01-07
申请号：US12261678
申请日：2009-09-03
申请人： Imran Ahmed , Leah Elizabeth Appel , Walter Christian Babcock , Dwayne Thomas Friesen , Scott Herbig , David Keith Lyon , Sheri L. Shamblin , Ravi Mysore Shanker , Daniel Tod Smithey , Steven C. Sutton , Avinash Govind Thombre , Kenneth C. Waterman , Jaymin C. Shah , Parag Suresh Shah , Peter Wisniecki , Dawn Renee Wagner
发明人： Imran Ahmed , Leah Elizabeth Appel , Walter Christian Babcock , Dwayne Thomas Friesen , Scott Herbig , David Keith Lyon , Sheri L. Shamblin , Ravi Mysore Shanker , Daniel Tod Smithey , Steven C. Sutton , Avinash Govind Thombre , Kenneth C. Waterman , Jaymin C. Shah , Parag Suresh Shah , Peter Wisniecki , Dawn Renee Wagner
IPC分类号： A61K9/14 , A61K31/501
CPC分类号： A61K9/1617 , A61K9/0004 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/5047 , A61K31/496 , A61K31/4965
摘要： A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.
摘要翻译： 提供了用于治疗哺乳动物中的精神病症例如精神分裂症的持续释放固体口服剂型，该口服剂型包含有效治疗所述精神病性障碍的量的齐拉西酮和药学上可接受的载体。
-
5.发明申请Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form 审中-公开溶解缓和形式和/或环糊精溶解增强形式的药物制剂制剂公开(公告)号：US20080075784A1
公开(公告)日：2008-03-27
申请号：US11622016
申请日：2005-07-11
IPC分类号： A61K31/715 , A61K31/4965 , A61K9/50
CPC分类号： A61K31/495 , A61K9/205
摘要： Improved taste masking of pharmaceutical compositions of unpleasant-tasting drugs and cyclodextrin is achieved by forming a mixture of drug and cyclodextrin wherein the drug's dissolution rate has been retarded, or the the cyclodextrin's dissolution rate has been enhanced, or by both.
摘要翻译： 通过形成药物和环糊精的混合物，其中药物的溶出速率已经被延迟，或者环糊精的溶解速度增加，或两者都是通过改善的令人不快的药物和环糊精的药物组合物的掩味来实现的。
-
6.发明申请Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase 有权胆固醇酯转运蛋白抑制剂和Hmg-Coa还原酶的药物组合物公开(公告)号：US20090118328A1
公开(公告)日：2009-05-07
申请号：US11920473
申请日：2006-05-22
申请人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
发明人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
IPC分类号： A61K31/4706 , A61K47/38 , A61K31/41 , A61K31/40 , A61K47/32
CPC分类号： A61K45/06 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K31/40 , A61K31/4706 , A61K2300/00
摘要： A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
摘要翻译： 固体无定形分散体包含胆固醇酯转移蛋白（CETP）抑制剂，3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶抑制剂）的抑制剂和浓度增强聚合物。 分散体中CETP抑制剂的至少主要部分是无定形的。 当施用于水性使用环境时，固体无定形分散体提供CETP抑制剂的浓度增强。
-
7.发明申请METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD 审中-公开方法，剂型和用于管理不含食物的ZIPRASIDONE的试剂盒公开(公告)号：US20110002989A1
公开(公告)日：2011-01-06
申请号：US12920400
申请日：2009-03-04
申请人： William John Curatolo , Scott Max Herbig , Avinash Govind Thombre , Jaymin Chandrakant Shah , Sheri L. Shamblin , Timothy Lukas , William Brett Caldwell , Dwayne Thomas Friesen , David Keith Lyon , Christopher Donovan Craig
发明人： William John Curatolo , Scott Max Herbig , Avinash Govind Thombre , Jaymin Chandrakant Shah , Sheri L. Shamblin , Timothy Lukas , William Brett Caldwell , Dwayne Thomas Friesen , David Keith Lyon , Christopher Donovan Craig
IPC分类号： A61K31/496 , A61P25/00 , A61K31/724 , A61K31/717 , A61K9/22
CPC分类号： A61K31/496
摘要： The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC0-inf) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC0-inf) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.
摘要翻译： 本发明提供了当人处于禁食状态时用人体中有效量的齐拉西酮治疗CNS病症的方法，剂型和试剂盒。 在一个实施方案中，本发明涉及一种用于治疗人类中枢神经系统疾病的方法，所述方法包括以禁食状态对人施用包含有效治疗所述CNS病症的量的齐拉西酮的固体口服剂型，其中 在所述给药之后，人体中齐拉西酮的血清浓度对时间曲线（AUC 0-inf）下的面积是由给药引起的齐拉西酮血清浓度对时间曲线（AUC 0-inf）的平均面积的70％至140％ 的控释齐拉昔酮立即释放口服胶囊含有相同数量的齐拉西酮至饲喂状态的人群。
-
8.发明授权Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase 有权胆固醇酯转移蛋白抑制剂和HMG-CoA还原酶的药物组合物公开(公告)号：US08828438B2
公开(公告)日：2014-09-09
申请号：US11920473
申请日：2006-05-22
申请人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
发明人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
CPC分类号： A61K45/06 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K31/40 , A61K31/4706 , A61K2300/00
摘要： A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
摘要翻译： 固体无定形分散体包含胆固醇酯转移蛋白（CETP）抑制剂，3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶抑制剂）的抑制剂和浓度增强聚合物。 分散体中CETP抑制剂的至少主要部分是无定形的。 当施用于水性使用环境时，固体无定形分散体提供CETP抑制剂的浓度增强。
-
公开(公告)号：US08207232B2
公开(公告)日：2012-06-26
申请号：US11569433
申请日：2005-05-18
申请人： Walter C. Babcock , Dwayne T. Friesen , David Keith Lyon , Warren Kenyon Miller , Daniel Tod Smithey
发明人： Walter C. Babcock , Dwayne T. Friesen , David Keith Lyon , Warren Kenyon Miller , Daniel Tod Smithey
CPC分类号： C08B13/00 , A61K9/146 , A61K9/1652 , A61K9/2054 , C08B11/08 , C08L1/284 , C08L1/32
摘要： Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.
摘要翻译： 公开了羟丙甲氧基，甲氧基，乙酰基和琥珀酰基具有独特取代度的羟丙基甲基纤维素乙酸琥珀酸酯（HPMCAS）和羟丙基甲基纤维素乙酸酯（HPMCA）的聚合物。 当用于制备包含低溶解度药物和这种聚合物的组合物时，聚合物提供增强的水性浓度和/或改善的物理稳定性。
-
公开(公告)号：US20100028440A1
公开(公告)日：2010-02-04
申请号：US12309438
申请日：2007-07-09
CPC分类号： A61K9/1694
摘要： A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes.
摘要翻译： 公开了用于从通过溶剂基方法形成的含药颗粒中除去残留溶剂的二次干燥方法。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.031 秒)
